Marc Ferrante (M Ferrante)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 50

Top Topics

Ulcerative Colitis

Top Venues

Journal of Crohn's & colitis

Alimentary pharmacology & therapeutics

Inflammatory bowel diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Matthias Lenfant, Bram Verstockt, João Sabino, Severine Vermeire, Marc Ferrante
Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' reply. Alimentary pharmacology & therapeutics 59 (8) (2024)
Matthias Lenfant, Bram Verstockt, João Sabino, Severine Vermeire, Marc Ferrante
Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply. Alimentary pharmacology & therapeutics 59 (5) (2024)
Remo Panaccione, Christopher Ma, Vipul Jairath, Axel Dignass, Namita Joshi, Ryan Clark, Jenny Griffith, Kristina Kligys, Monika Semwal, Zachary Smith, Dominic Mitchell, Dominic Nunag, Marc Ferrante
Achievement of Endoscopic Remission After Induction Reduces Hospitalization Burden in Crohn's Disease: Findings From a Pooled Post Hoc Analysis of Risankizumab and Upadacitinib Phase III Trials. Journal of Crohn's & colitis (2024)
Matthias Lenfant, Bram Verstockt, João Sabino, Severine Vermeire, Marc Ferrante
Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' reply. Alimentary pharmacology & therapeutics 59 (8) (2024)
Dahham Alsoud, João Sabino, Denis Franchimont, Anneline Cremer, Julie Busschaert, François D'Heygere, Peter Bossuyt, Anne Vijverman, Séverine Vermeire, Marc Ferrante
Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn's Disease: A Belgian Multicentric Cohort Study. Inflammatory bowel diseases (2024)
Matthias Lenfant, Bram Verstockt, João Sabino, Severine Vermeire, Marc Ferrante
Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply. Alimentary pharmacology & therapeutics 59 (5) (2024)
Silvio Danese, Axel Dignass, Katsuyoshi Matsuoka, Marc Ferrante, Millie Long, Isabel Redondo, Richard Moses, Sebastian Maier, Theresa Hunter Gibble, Nathan Morris, Catherine Milch, Maria T Abreu
Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Program. Journal of Crohn's & colitis (2024)
Anouk Teugels, Ilse van den Eijnden, Bep Keersmaekers, Bram Verstockt, João Sabino, Severine Vermeire, Livia Guadagnoli, Ilse Van Diest, Marc Ferrante
Disease Acceptance, but not Perceived Control, is Uniquely Associated with Inflammatory Bowel Disease-related Disability. Journal of Crohn's & colitis 18 (7) (2024)
Anouk Teugels, Ilse van den Eijnden, Bep Keersmaekers, Bram Verstockt, João Sabino, Séverine Vermeire, Livia Guadagnoli, Ilse Van Diest, Marc Ferrante
Disease acceptance, but not perceived control, is uniquely associated with inflammatory bowel disease-related disability. Journal of Crohn's & colitis (2024)
Stefan Schreiber, Raymond K Cross, Remo Panaccione, Geert D'Haens, Peter Bossuyt, Iris Dotan, Jean Frederic Colombel, Edouard Louis, Marla C Dubinsky, Kristina Kligys, Ezequiel Neimark, Alexandra Song, Javier Zambrano, Jasmina Kalabic, Erica Cheng, Yafei Zhang, Marc Ferrante
Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease. Alimentary pharmacology & therapeutics (2024)
Pauline Riviere, Gabriele Bislenghi, Nassim Hammoudi, Bram Verstockt, Steven Brown, Melissa Oliveira-Cunha, Willem Bemelman, Gianluca Pellino, Paulo Gustavo Kotze, null null, Marc Ferrante, Yves Panis
Results of the Eighth Scientific Workshop of ECCO: Pathophysiology and risk factors of postoperative Crohn's disease recurrence after an ileocolic resection. Journal of Crohn's & colitis (2023)
Marc Ferrante
Editorial: risankizumab - ready to break ceilings? Alimentary pharmacology & therapeutics 57 (8) (2023)
Marc Ferrante, Peter M Irving, Maria T Abreu, Jeffrey Axler, Xiang Gao, Qian Cao, Toshimitsu Fujii, Astrid Rausch, Joanna Torres, Ezequiel Neimark, Alexandra Song, Kori Wallace, Kristina Kligys, Sofie Berg, Xiaomei Liao, Qing Zhou, Jasmina Kalabic, Brian Feagan, Remo Panaccione
Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial. Journal of Crohn's & colitis (2023)
Séverine Vermeire, Jurij Hanzel, Mark Löwenberg, Marc Ferrante, Peter Bossuyt, Frank Hoentjen, Denis Franchimont, Károly Palatka, Harald Peeters, Aart Mookhoek, Gert de Hertogh, Tamás Molnár, Wouter van Moerkercke, Triana Lobatón, Esmé Clasquin, Melanie S Hulshoff, Filip Baert, Geert D'Haens, null null
Early versus Late Use of Vedolizumab in Ulcerative Colitis: Clinical, Endoscopic, and Histological Outcomes. Journal of Crohn's & colitis (2023)
Bram Verstockt, Valerie Pivorunas, Naim Al Mahi, Nizar Smaoui, Heath Guay, Nicholas A Kennedy, James R Goodhand, Simeng Lin, Benjamin Y H Bai, Stephen B Hanauer, Marc Ferrante, Julian Panés, Séverine Vermeire
Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies. Journal of Crohn's & colitis (2023)
Wannee Kantasiripitak, Sebastian G Wicha, Debby Thomas, Ilse Hoffman, Marc Ferrante, Séverine Vermeire, Karen van Hoeve, Erwin Dreesen
A model-based tool for guiding infliximab induction dosing to maximise long-term deep remission in children with inflammatory bowel diseases. Journal of Crohn's & colitis (2023)
Gabriele Dragoni, Mariangela Allocca, Pär Myrelid, Nurulamin M Noor, Nassim Hammoudi, null null, Pauline Riviere, Yves Panis, Marc Ferrante
Results of the Eighth Scientific Workshop of ECCO: Diagnosing postoperative recurrence of Crohn's disease after an ileocolonic resection with ileocolonic anastomosis. Journal of Crohn's & colitis (2023)
Stefan Schreiber, Silvio Danese, Axel Dignass, Eugeni Domènech, Massimo C Fantini, Marc Ferrante, Jonas Halfvarson, Ailsa Hart, Fernando Magro, Charlie W Lees, Salvo Leone, Marieke J Pierik, Michele Peters, Polly Field, Helen Fishpool, Laurent Peyrin-Biroulet
Defining Comprehensive Disease Control for use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations. Journal of Crohn's & colitis (2023)
Liselotte Fierens, Nicholas Carney, Gottfried Novacek, C Janneke van der Woude, Britta Siegmund, Francesc Casellas, Natalia Borruel, Anouk S Huberts, Elena Sonnenberg, Nathalie Gerold, Christian Primas, Charlotte Rose Hedin, Tanja Stamm, Mette Julsgaard, Gionata Fiorino, Radice Simona, Michela Luciana Luisa Zini, Evelyn Gross, Cornelia Sander, Ingrid Arijs, Vasiliki-Rafaela Vakouftsi, Tunde Koltai, null null, null null, Iliàs Charlafti, Marc Ferrante
A Core Outcome Set for inflammatory bowel diseases: development and recommendations for implementation in clinical practice through an international multi-stakeholder consensus process. Journal of Crohn's & colitis (2023)
Matthias Lenfant, Bram Verstockt, João Sabino, Severine Vermeire, Marc Ferrante
The assessment of segmental healing by the Modified Mayo Endoscopic Score (MMES) complements the prediction of long-term clinical outcomes in patients with ulcerative colitis. Alimentary pharmacology & therapeutics (2023)
Marc Ferrante, Lieven Pouillon, Míriam Mañosa, Edoardo Vincenzo Savarino, Matthieu Allez, Christina Kapizioni, Naila Arebi, Michele Carvello, Pär Myrelid, Annemarie C De Vries, null null, Pauline Riviere, Yves Panis, Eugeni Domènech
Results of the Eighth Scientific Workshop of ECCO: Prevention and treatment of postoperative recurrence in patients with Crohn's disease undergoing an ileocolonic resection with ileocolonic anastomosis. Journal of Crohn's & colitis (2023)
Gabriele Bislenghi, Julie Van Den Bossch, Steffen Fieuws, Albert M Wolthuis, Marc Ferrante, Gert de Hertogh, Severine Vermeire, André D'Hoore
Appearance of the Bowel and Mesentery During Surgery Is Not Predictive of Postoperative Recurrence After Ileocecal Resection for Crohn's Disease: A Prospective Monocentric Study. Inflammatory bowel diseases (2023)
Wannee Kantasiripitak, Zhigang Wang, Isabel Spriet, Marc Ferrante, Erwin Dreesen
Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases. Expert review of clinical pharmacology 14 (12) (2022)
Kaline Arnauts, Padhmanand Sudhakar, Sare Verstockt, Cynthia Lapierre, Selina Potche, Clara Caenepeel, Bram Verstockt, Jeroen Raes, Severine Vermeire, João Sabino, Catherine M Verfaillie, Marc Ferrante
Microbiota, not host origin drives ex vivo intestinal epithelial responses. Gut microbes 14 (1) (2022)
Julian Panes, Gerd Bouma, Marc Ferrante, Torsten Kucharzik, Maria Nachury, Fernando de la Portilla de Juan, Walter Reinisch, Francesco Selvaggi, Jörg Tschmelitsch, Neil R Brett, Martin Ladouceur, Matthias Binek, Gary Hantsbarger, Sarah Campbell-Hill, Chitra Karki, Christianne Buskens
INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn's Disease Treated in the ADMIRE-CD Trial. Inflammatory bowel diseases 28 (11) (2022)
Elise Schoefs, Séverine Vermeire, Marc Ferrante, João Sabino, Tessy Lambrechts, Luisa Avedano, Isabella Haaf, Maria Stella De Rocchis, Andrea Broggi, Magdalena Sajak-Szczerba, Roberto Saldaña, Rosanne Janssens, Isabelle Huys
What are the unmet needs and most relevant treatment outcomes according to patients with inflammatory bowel disease? A qualitative patient preference study. Journal of Crohn's & colitis (2022)
Dahham Alsoud, Gert De Hertogh, Griet Compernolle, Sophie Tops, João Sabino, Marc Ferrante, Debby Thomas, Severine Vermeire, Bram Verstockt
Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis. Journal of Crohn's & colitis 16 (10) (2022)
Pauline Riviere, Joel Pekow, Nassim Hammoudi, Pauline Wils, Peter De Cruz, Christina Pu Wang, Míriam Mañosa, Jacob Ollech, Matthieu Allez, Maria Nachury, Michael A Kamm, Maya Ahanori, Marc Ferrante, Anthony Buisson, Siddarth Singh, David Laharie, Momar Diouf, Mathurin Fumery
Comparison of the risk of Crohn's disease postoperative recurrence between modified Rutgeerts score i2a and i2b categories: an individual patient data meta-analysis. Journal of Crohn's & colitis (2022)
Lucas Wauters, Raul Y Tito, Matthias Ceulemans, An Outtier, Leen Rymenans, Chloë Verspecht, João Sabino, Marc Ferrante, Severine Vermeire, Tim Vanuytsel, Jeroen Raes
Microbiome variance of the small bowel in Crohn's disease. Gut 72 (8) (2022)
Marc Ferrante, Peter M Irving, Christian Philipp Selinger, Geert R A M D'Haens, Tanja Kuehbacher, Ursula E Seidler, Savion Gropper, Thomas Haeufel, Sebastiano Forgia, Silvio Danese, Jochen Klaus, Brian G Feagan
Safety and tolerability of spesolimab in patients with ulcerative colitis. Expert opinion on drug safety (2022)
Wannee Kantasiripitak, Marc Ferrante, Sebastian Georg Wicha, Alexander Kensert, Zhigang Wang, João Sabino, Severine Vermeire, Debby Thomas, Marc Ferrante, Erwin Dreesen
Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases. CPT: pharmacometrics & systems pharmacology 11 (8) (2022)
Liselotte Fierens, Claire Liefferinckx, Eveline Hoefkens, Triana Lobatòn, Erwin Dreesen, João Sabino, Marc Ferrante
Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies. Journal of Crohn's & colitis 16 (7) (2022)
Padhmanand Sudhakar, Judith Wellens, Bram Verstockt, Marc Ferrante, João Sabino, Severine Vermeire
Holistic healthcare in inflammatory bowel disease: time for patient-centric approaches? Gut (2022)
Annick Moens, Nasim Sadat Seyed Tabib, Vera Ballet, João Sabino, Séverine Vermeire, Marc Ferrante
Safety of sequential biological therapy in inflammatory bowel disease: results from a tertiary referral centre. Alimentary pharmacology & therapeutics 56 (2) (2022)
Joanna Torres, María Chaparro, Mette Julsgaard, Konstantinos Katsanos, Zuzana Zelinkova, Manasi Agrawal, Sandro Ardizzone, Marjo J E Campmans-Kuijpers, Gabriele Dragoni, Marc Ferrante, Gionata Fiorino, Emma K Flanagan, Catarina Geraldes de Frias Gomes, Ailsa Hart, Charlotte Rose Hedin, Pascal Juillerat, Annemarie Mulders, Pär Myrelid, Aoibhlinn O'Toole, Pauline Riviere, Michael Scharl, Christian Philipp Selinger, Elena Sonnenberg, Murat Toruner, Jantien Wieringa, C Janneke Van der Woude
European Crohn's and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation. Journal of Crohn's & colitis (2022)
Neeraj Narula, Emily Chu Lee Wong, Jean Frederic Colombel, William J Sandborn, Marc Ferrante, John K Marshall, Walter Reinisch, Parambir S Dulai
Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for One-Year Endoscopic Remission in Moderate to Severe Crohn's Disease. Journal of Crohn's & colitis (2021)
Marta Walentynowicz, Iris van de Pavert, Liselotte Fierens, Sofie Coenen, Johan W S Vlaeyen, Andreas von Leupoldt, Lukas Van Oudenhove, Séverine Vermeire, Gert Van Assche, Marc Ferrante, Ilse Van Diest
Inflammatory Bowel Disease-related Behaviours [IBD-Bx] questionnaire: Development, validation, and prospective associations with fatigue. Journal of Crohn's & colitis (2021)
Annick Moens, Bram Verstockt, Dahham Alsoud, João Sabino, Marc Ferrante, Severine Vermeire
Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD. Inflammatory bowel diseases (2021)
C Jorissen, Bram Verstockt, N Schils, João Sabino, Marc Ferrante, Severine Vermeire
Long-term clinical outcome after thiopurine discontinuation in elderly IBD patients. Scandinavian journal of gastroenterology 56 (11) (2021)
Brecht Creyns, Jonathan Cremer, Gert De Hertogh, Louis Boon, Marc Ferrante, Severine Vermeire, Gert Van Assche, Jan L Ceuppens, Christine Breynaert
Fibrogenesis in chronic murine colitis is independent of innate lymphoid cells. Immunity, inflammation and disease 8 (3) (2020)
Ho-Su Lee, Maaike Vancamelbeke, Sare Verstockt, Tom Wilms, Bram Verstockt, João Sabino, Marc Ferrante, Séverine Vermeire, Isabelle Cleynen
Molecular Changes in the Non-Inflamed Terminal Ileum of Patients with Ulcerative Colitis. Cells 9 (8) (2020)
Bram Verstockt, Marc Ferrante
Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological era-getting nearer? Alimentary pharmacology & therapeutics 51 (7) (2020)
Bram Verstockt, Séverine Vermeire, Marc Ferrante, Christine Breynaert
Editorial: biomarker predictors of non-response to TNFα antagonists - the quest continues. Authors' reply. Alimentary pharmacology & therapeutics 49 (8) (2020)
Bram Verstockt, Liesbeth Boets, João Sabino, Séverine Vermeire, Marc Ferrante
Thiopurine monotherapy has a limited place in treatment of patients with mild-to-moderate Crohn's disease. Gut 70 (7) (2020)
Bram Verstockt, Sare Verstockt, Brecht Creyns, Sophie Tops, Gert Van Assche, Ann Gils, Jan L Ceuppens, Séverine Vermeire, Marc Ferrante, Christine Breynaert
Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease. Alimentary pharmacology & therapeutics 49 (5) (2019)
Annick Moens, C Janneke van der Woude, Mette Julsgaard, Evelien Humblet, Juliette Sheridan, Daniel C Baumgart, Cyrielle Gilletta De Saint-Joseph, Stéphane Nancey, Jean-François Rahier, Peter Bossuyt, Anneline Cremer, Sophie Dewit, Carl Eriksson, Frank Hoentjen, Thomas Krause, Edouard Louis, Elisabeth Macken, Zoran Milenkovic, Jochen Nijs, Annelies Posen, Anneleen Van Hootegem, Wouter Van Moerkercke, Séverine Vermeire, Ariella Bar-Gil Shitrit, Marc Ferrante
Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Alimentary pharmacology & therapeutics 51 (1) (2019)
Bram Verstockt, Gitte Moors, Sumin Bian, Thomas Van Stappen, Gert Van Assche, Severine Vermeire, Ann Gils, Marc Ferrante
Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing. Alimentary pharmacology & therapeutics 48 (7) (2018)
Bram Verstockt, Severine Vermeire, Gert Van Assche, Marc Ferrante
When IBD is not IBD. Scandinavian journal of gastroenterology 53 (9) (2018)
E Dreesen, T Van Stappen, V Ballet, M Peeters, G Compernolle, S Tops, K Van Steen, G Van Assche, Marc Ferrante, S Vermeire, Ann Gils
Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response. Alimentary pharmacology & therapeutics 47 (3) (2017)
S Van Steenbergen, S Bian, S Vermeire, G Van Assche, A Gils, Marc Ferrante
Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control study. Alimentary pharmacology & therapeutics 45 (7) (2017)